Matthew Sykes
Stock Analyst at Goldman Sachs
(4.03)
# 584
Out of 5,043 analysts
210
Total ratings
55.48%
Success rate
10.14%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $10.39 | -51.88% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.15 | -27.71% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $13.59 | -52.17% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $38.64 | +16.46% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $8.10 | -1.23% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $34.18 | +40.43% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $16.71 | +1.74% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $182.03 | -12.10% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $10.16 | -1.57% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $97.16 | +28.65% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $15.11 | -7.35% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $221.01 | +8.59% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $14.51 | +79.19% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $195.28 | -12.95% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $70.85 | -20.96% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $130.66 | -38.77% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $2.09 | -28.23% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $192.22 | -1.15% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $1.35 | +29.63% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.34 | +27.25% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $35.97 | +2.86% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $63.50 | +2.36% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $217.43 | +14.98% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.68 | +322.54% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,419.71 | -8.43% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $13.39 | -10.38% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $563.78 | +13.52% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $146.59 | -1.08% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.40 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $10.39
Upside: -51.88%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.15
Upside: -27.71%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $13.59
Upside: -52.17%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $38.64
Upside: +16.46%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $8.10
Upside: -1.23%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $34.18
Upside: +40.43%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $16.71
Upside: +1.74%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $182.03
Upside: -12.10%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $10.16
Upside: -1.57%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $97.16
Upside: +28.65%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $15.11
Upside: -7.35%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $221.01
Upside: +8.59%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $14.51
Upside: +79.19%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $195.28
Upside: -12.95%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $70.85
Upside: -20.96%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $130.66
Upside: -38.77%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $2.09
Upside: -28.23%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $192.22
Upside: -1.15%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $1.35
Upside: +29.63%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.34
Upside: +27.25%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $35.97
Upside: +2.86%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $63.50
Upside: +2.36%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $217.43
Upside: +14.98%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.68
Upside: +322.54%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,419.71
Upside: -8.43%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $13.39
Upside: -10.38%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $563.78
Upside: +13.52%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $146.59
Upside: -1.08%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $48.40
Upside: -